drugset / Trial / NCT02718521

Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN

NCT02718521

Unknown 400 enrolled Chinese PLA General Hospital
RandomizedParallel-groupTriple-blindPrevention

Summary

Patients at moderate and high risk for contrast induced nephropathy (CIN) should receive sufficient hydration before application of contrast to prevent CIN, but hydration could obviously increase the preload for congestive heart failure (CHF) patients. Isosorbide Dinitrate could reduce cardiac preload and afterload by expanding vein and artery.so adequate hydration therapy combined with intravenous infusion of isosorbide dinitrate could better prevent contrast-induced nephropathy theoretically.This prospective, randomized, double-blind, comparative clinical trial randomly selected 264 patients with estimated glomerular filtration rate, (eGFR) \<60 ml/min per 1.73 m2 and CHF undergoing coronary angiography to receive either the convention hydration (n=200) or the hydration therapy combined with intravenous infusion of isosorbide dinitrate(n=200).

Timeline

Start
2016-03
Primary completion
2017-03
Completion
2017-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Isosorbide Dinitrate Other / unclassified 2 mg Intravenous
Background sodium chloride Unknown 0.5 unknown Intravenous
Background sodium chloride Unknown 1 unknown Intravenous

Indications